Consensus Molecular Subtype 4 (CMS4) Identifies RAS Wild-Type mCRC Patients Who May Benefit Preferentially from Anti‑EGFR Therapy
An individual patient data meta-analysis of 790 RAS wild-type metastatic colorectal cancer patients suggests CMS4 tumors derive meaningful progression-free and overall survival benefit from anti‑EGFR versus anti‑VEGF antibodies, warranting prospective validation.
